Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elaine Y Kang

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Molecular Therapy. Nucleic Acids|December 16, 2025
Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapyElaine Y Kang, Dongfang Wang, Damian Kaniowski, et al.
Pediatrics in Review|November 3, 2004
Index of suspicionMuhammad Waseem, Abid Hussain, Elaine Y Kang, et al.
The Journal of Physiology|July 25, 2003
Reduced left ventricular compliance and mechanical efficiency after prolonged inhibition of NO synthesis in conscious dogsHeiner Post, Chiara d'Agostino, Vincenzo Lionetti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 25, 2025
Cell-selective telomere damage by thiopurine-based oligonucleotide for diffuse large B cell lymphoma immunotherapyChunsong Yu, Elaine Y Kang, Dongfang Wang, et al.
Lancet (London, England)|July 12, 2005
A floppy child with failure to thriveIngrid Loma-Sanner, Elaine Y Kang, Sara Sepehrdad, et al.
Neuro-Oncology|April 11, 2025
Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockadeChia-Yang Hung, Elaine Y Kang, Karol Jacek, et al.
Molecular Therapy. Oncology|May 25, 2026
Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studiesRachael Mooney, Gary Ngai, Gurmeet Kaur, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Molecular Therapy. Nucleic Acids|December 16, 2025
Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapyElaine Y Kang, Dongfang Wang, Damian Kaniowski, et al.
Pediatrics in Review|November 3, 2004
Index of suspicionMuhammad Waseem, Abid Hussain, Elaine Y Kang, et al.
The Journal of Physiology|July 25, 2003
Reduced left ventricular compliance and mechanical efficiency after prolonged inhibition of NO synthesis in conscious dogsHeiner Post, Chiara d'Agostino, Vincenzo Lionetti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 25, 2025
Cell-selective telomere damage by thiopurine-based oligonucleotide for diffuse large B cell lymphoma immunotherapyChunsong Yu, Elaine Y Kang, Dongfang Wang, et al.
Lancet (London, England)|July 12, 2005
A floppy child with failure to thriveIngrid Loma-Sanner, Elaine Y Kang, Sara Sepehrdad, et al.
Neuro-Oncology|April 11, 2025
Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockadeChia-Yang Hung, Elaine Y Kang, Karol Jacek, et al.
Molecular Therapy. Oncology|May 25, 2026
Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studiesRachael Mooney, Gary Ngai, Gurmeet Kaur, et al.
Pageof 1